Tag: FDA
As the Opioid Epidemic Worsens, We Must Look at Free Market Solutions
Prior to covid-19, it was the opioid epidemic that worried U.S. officials, with reports showing that the abuse of opioids nationwide was contributing to increased healthcare costs and overdose deaths. In 2020, however, things changed. With covid came lockdowns, and with the lockdowns came unemployment, isolation, and depression.  By early 2021, the Centers for...
Read More »
New Alzheimer’s Drug Approval Could Change the FDA’s Approval Process for the Better
After the experimental treatment for Alzheimer’s named aducanumab failed a futility test, its producers Biogen and Eisai lost hope the Food and Drug Administration would ever approve it. Despite promising clinical results through the approval process, the producers abandoned their project in 2019.  Eight months later, Biogen developed an expanded dataset to reassess aducanumab’s impact...
Read More »
Ecstasy Nears FDA Approval to Treat Severe Post-Traumatic Stress Disorder
In a heart-wrenching story written in 2017, Rachael Kaplan details her lifelong struggles with Post Traumatic Stress Disorder (PTSD). Enduring chronic and severe abuse as a child, Rachael strongly considered ending her life and found herself “praying to die.” She worked with several therapists and numerous multiple treatment methods to improve her condition. Unfortunately,...
Read More »
AstraZeneca Vaccine Controversy Provides Another Example of Overly Cautious Government Reactions
After a sluggish and error-prone beginning to a country-wide effort to vaccinate Americans against Covid-19, it seems things are quickly improving. According to the Centers for Disease Control, as of March 18th, nearly 113 million Americans have received at least Covid-19 vaccination (two of the three available vaccines require two separate injections). The agency...
Read More »
The FDA Should Grant Emergency Use Authorization for Alzheimer’s Drug
In March 2019, an experimental drug designed to treat Alzheimer’s disease named aducanumab failed a futility test during the process for approval from the Food and Drug Administration. Facing seemingly little hope for success, aducanumab’s producers Biogen and Eisai strongly considered abandoning the project. However, when the drugmakers conducted further analysis on a larger...
Read More »
New COVID-19 Vaccines, Same Sluggish FDA
In October, large portions of the United States began experiencing rapid increases in new COVID-19 cases. Many European countries have experienced a similar surge in cases, even after being devastated by severe COVID-19 outbreaks earlier this year. Fearing the arrival of a second wave, several states reenacted various lockdown measures to curb spreading disease....
Read More »
FDA Approves Blood Plasma as Covid-19 Treatment
In the nearly eight months since Covid-19 arrived in the United States, the country has undergone extensive lockdowns, trying economic hardship, and prolonged social isolation. Despite these sacrifices to battle the pandemic, the U.S. continues to lead the world in total confirmed Covid-19 cases and Covid-19 fatalities. As of September 9, the Coronavirus Resource...
Read More »
Promising Alzheimer’s Drug on FDA Fast Track
Well before Covid-19 emerged, medical researchers warned that the rapid increase of Alzheimer’s disease in older populations would lead to the next “pandemic.” In many respects, they were right. According to the Alzheimer’s Association, nearly 10 percent of the U.S. population over 65 years old suffers from that progressively destructive brain disorder. The same...
Read More »
To Make Drugs More Affordable, President Trump Should Focus on Price Competition
President Trump has tried seemingly everything to lower prescription drug prices. In 2018 alone, he established an international pricing index to prevent overcharging from foreign drug producers, targeted drug rebates between producers and middlemen, and granted Medicare Part D plans more authority to negotiate drug prices. Despite these and other efforts, the prices for thousands of...
Read More »
Keep Government Out of Developing a COVID-19 Vaccine
In late March, California became the first state to issue mandatory “shelter in place” orders. By mid-April, nearly 94 percent of the U.S. population was under order to stay at home. Nearly three months later, millions are still desperate to get back to their lives. Protest rallies held to “reopen the economy” have emerged...
Read More »
  • Catalyst
  • MyGovCost.org
  • FDAReview.org
  • OnPower.org
  • elindependent.org